The Abl oncogene was initially identified as the viral transforming gene of Abelson murine leukemia virus (A-MuLV). The major translational product of c-Abl has been identified as a protein with tyrosine kinase activity and an SH2 domain. The Abl oncogene is implicated in several human leukemias including 90-95% of chronic myelocytic leukemia (CML), 20-25% of adult acute lymphoblastic leukemia (ALL) and 2-5% of pediatric ALL. In these leukemias the c-Abl proto-oncogene undergoes a (9;22) chromosomal translocation producing the Philadelphia (Ph1) chromosome. The molecular consequence of this translocation is the generation of a chimeric Bcr/c-Abl mRNA encoding activated Abl protein-tyrosine kinase.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: Abelson murine leukemia oncogene; Abelson murine leukemia viral oncogene homolog 1; Abelson murine leukemia viral oncogene homolog 2; Abelson tyrosine-protein kinase 1; Abelson tyrosine-protein kinase 2; Abelson-related gene protein; abl2; bcr/c-abl oncogene protein; c-abl oncogene 1, receptor tyrosine kinase; c-abl oncogene 2, non-receptor tyrosine kinase; p150; Proto-oncogene c-Abl; proto-oncogene tyrosine-protein kinase ABL1; tyrosine kinase ARG; Tyrosine-protein kinase ABL1; Tyrosine-protein kinase ABL2; Tyrosine-protein kinase ARG; v-abl Abelson murine leukemia oncogene 1; v-abl Abelson murine leukemia viral oncogene homolog 1; v-abl Abelson murine leukemia viral oncogene homolog 2; v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related gene)
Gene Aliases: AA536808; ABL; ABL1; ABL2; ABLL; AI325092; ARG; bcr/abl; c-ABL; c-ABL1; E430008G22Rik; JTK7; p150; v-abl